| 0 (0%) | 01-19 18:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.28 | 1-year : | 2.67 |
| Resists | First : | 1.96 | Second : | 2.28 |
| Pivot price | 1.56  |
|||
| Supports | First : | 1.49 |
Second : | 1.21 |
| MAs | MA(5) : | 1.77 |
MA(20) : | 1.52 |
| MA(100) : | 1.39 |
MA(250) : | 1.05 |
|
| MACD | MACD : | 0.1  |
Signal : | 0 |
| %K %D | K(14,3) : | 64 |
D(3) : | 77.8 |
| RSI | RSI(14): 57.9 |
|||
| 52-week | High : | 1.96 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCGN ] has closed below upper band by 31.8%. Bollinger Bands are 87.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.84 - 1.85 | 1.85 - 1.86 |
| Low: | 1.61 - 1.62 | 1.62 - 1.63 |
| Close: | 1.68 - 1.69 | 1.69 - 1.7 |
Thu, 15 Jan 2026
A Look At Ocugen (OCGN) Valuation After New OCU410 And OCU410ST Trial Results - simplywall.st
Thu, 15 Jan 2026
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Thu, 15 Jan 2026
Ocugen (OCGN) Reports 46% Lesion Reduction in OCU410 Mid-Stage Trial - Intellectia AI
Thu, 15 Jan 2026
OCGN: OCU410 gene therapy reduced GA lesion growth by 46% at 12 months with strong safety and durability - TradingView — Track All Markets
Thu, 15 Jan 2026
Ocugen (OCGN) Reports Promising Mid-Stage Trial Results for OCU410 - GuruFocus
Thu, 15 Jan 2026
Ocugen posts mid-stage trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 312 (M) |
| Held by Insiders | 3.0765e+008 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 59,090 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.751e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 81.2 % |
| Return on Equity (ttm) | -63.7 % |
| Qtrly Rev. Growth | 5.37e+006 % |
| Gross Profit (p.s.) | 11.93 |
| Sales Per Share | -63.87 |
| EBITDA (p.s.) | -7.04846e+006 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 767.26 |
| Dividend | 0 |
| Forward Dividend | 5.899e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|